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3Abstract37
Background and objective: Chronic obstructive pulmonary disease and low vitamin D status38
predict mortality, but their combined effect on mortality remains inconclusive. We aimed to39
investigate a joint effect of airway obstruction and vitamin D status on mortality in a40
nationally representative cohort.41
Methods: We analysed data of 6676 Finnish adults participating between 1978 and 1980 in a42
national health examination survey, undergoing spirometry and having all necessary data43
collected. We followed them up in national registers through record linkage until 3144
December 2011. We categorised the subjects with obstruction using the lower limit of normal45
(LLN) and the measured serum 25-hydroxyvitamin-D (s-25(OH)D) into tertiles.46
Results: Both obstruction and low s-25(OH)D independently predicted mortality in a47
multivariate model adjusted also for age, sex, smoking, education, leisure physical activity,48
body mass index, asthma and serum C-reactive protein. However, a statistically significant (p49
= 0.007) interaction emerged: the adjusted mortality HRs (95% CI’s) for s-25(OH)D in50
tertiles among the subjects without and with obstruction were 1.00 (lowest), 0.96 (0.87–1.05)51
and 0.89 (0.81–0.98); and 1.00, 0.96 (0.71–1.31) and 0.57 (0.40–0.80), respectively.52
Conclusions: In conclusion, obstruction and low s-25(OH)D predict mortality independently53
of each other. Our findings suggest that low vitamin D status might be particularly54
detrimental among subjects with obstruction.55
4Introduction56
Low vitamin D status and chronic obstructive pulmonary disease (COPD) are common57
underdiagnosed conditions worldwide. Inadequate exposure to sunlight and an insufficient58
intake from dietary sources induces a low vitamin D status, generally measured as serum 25-59
hydroxyvitamin-D (s-25(OH)D) concentrations (<30 nmol/L determined as deficiency). The60
prevalence of s-25(OH)D deficiency is currently up to 30% in Europe and 0.6% in Finland,61
yet over 30 years ago >20% of our study population suffered from a low s-25(OH)D (1-5). In62
COPD, a progressing airway obstruction primarily caused by smoking leads to early death.63
Globally, COPD prevalence is 10.1%, falling to 4.3% and 3.1%, respectively, among Finnish64
men and women (6-8).65
Previous studies have shown both associations between COPD and low s-25(OH)D and66
between decreasing lung function measures and 25(OH)D concentrations (1,9-11). However,67
the link between COPD and vitamin D metabolism remains unconfirmed. As such, a low s-68
25(OH)D evidently plays a role in regulating inflammatory reactions in COPD (1,3,12). Low69
s-25(OH)D and COPD are associated with similar factors, such as ageing, a low70
socioeconomic status, smoking, physical inactivity and chronic diseases (1,3,6,13,14). Yet,71
limited longitudinal data exist on the association between COPD and low s-25(OH)D (12).72
Low s-25(OH)D and COPD predict premature death—COPD by decreasing lung function and73
the s-25(OH)D by decreasing concentration (6,13-18). Whether low s-25(OH)D has a similar74
or different association with mortality in subjects with COPD than in general population75
remains less studied and inconclusive (19-21).76
Thus, we aimed to analyse whether a low s-25(OH)D confounds or modifies the association77
between airway obstruction and mortality during a long follow-up.78
579
Material and methods80
81
Study population82
The Mini-Finland Health Survey, a population-based nationally representative health83
examination survey, consists of a two-stage cluster performed between 1978 and 1980 (22). In84
all 40 nationally representative areas with 40 000 to 60 000 subjects living on them were85
selected for inclusion in the first stage; and a representative sample of Finnish adults (363786
men and 4363 women) aged 30 to 91 from each area was selected from the population register87
in the second stage. Each subject in the population of each area had an equal probability for88
selection (probability proportional to size sampling). From this sample, 7217 (90%) subjects89
participated in the survey. Our study included 6676 subjects (3091 men and 3585 women) for90
whom was collected all relevant health information and who underwent a comprehensive91
health examination, including spirometry (22-25).92
93
Measurements and definition of determinants94
Laboratory technicians with special training performed spirometry using a Vitalograph95
spirometer (Vitalograph Ltd., Buckingham, England) following standard guidelines and96
instructions. Technicians presented the test procedure individually to each subject. Ideally,97
each participant produced minimum two spirometry curves, as consistent as possible, reaching98
an adequate and high-quality forced expiratory volume in 1 s (FEV1) and forced vital capacity99
(FVC). The FEV1/FVC was determined using the highest readings for FEV1 and FVC from100
6the technically acceptable measurements for the air temperature and pressure, saturated with101
water vapour (BTPS) values (spirometry technique used in Mini-Finland Health Survey).102
Spirometry was performed without bronchodilation (22,23,25).103
Individual lung function results were calculated using the Global Lung Function Initiative104
(GLI) reference values which were derived from the spirometry records of 97,759 multi-105
ethnic, healthy non-smokers aged 3 to 95. The GLI reference values were determined for four106
separate ethnic groups, and we only applied the reference values for Caucasians. Subjects107
with FEV1/FVC values below the lower limit of normal (LLN) using reference values were108
classified as having airway obstruction while others did not have obstruction (26,27).109
Height and weight were measured. Body mass index (BMI) (weight (kg)/height² (m²)) was110
used as a measure of relative weight. Age, sex, leisure physical activity and educational levels111
were collected through a basic questionnaire. Leisure physical activity was determined112
through questions on the frequency, intensity and duration of physical activity and further113
categorized as inactive (little physical exercise), occasionally active (exercise alongside some114
hobbies or irregular exercise) and regularly active (regular exercise). The completed number115
of years of schooling classified educational levels in basic (<8 years), intermediate (8–12116
years) and higher (>12 years) (22-25).117
A standard interview inquired smoking habits, and these were categorized as never, former118
and current smokers. Former smokers had quit smoking minimum one month before the119
baseline survey. All subjects who had smoked at least one pipe, cigar or cigarette daily or120
almost daily during the year before the survey were categorised as current smokers. Current121
smokers were further categorized into two groups based on the number of daily smoked122
cigarettes: 1 to 19 and ≥20 cigarettes (22-25).123
7Fasting blood samples were taken during the health examination and stored frozen at −20°C.124
s-25(OH)D concentration was determined in 2003 using radioimmunoassay (DiaSorin, Inc.,125
Stillwater, Minnesota, USA). The inter-assay coefficient of variation for s-25(OH)D126
determination was 7.80% at a mean level of 47.3 nmol/L (n = 167) and 9.12% at 131.3127
nmol/L (n = 135). The proportion of quality-control samples was 13.5% (5,28). In this study,128
no single cut-off limit was used to define low s-25(OH)D. We classified s-25(OH)D129
concentrations into tertiles: 5–32 nmol/L, 33–48 nmol/L and 49–180 nmol/L; the130
concentrations approximated international definitions for vitamin D deficiency (<30 nmol/L)131
and insufficiency (30–49.9 nmol/L) (4).132
In Finland, situated geographically between the latitudes 60°N and 70°N, biologically133
effective ultraviolet B irradiation producing vitamin D through the skin by sunshine is only134
possible during the summer months. When our baseline study was performed, s-25(OH)D135
concentrations were higher between May and October (2,5). Yet, baseline examinations were136
conducted during different seasons. Therefore, we divided subjects into two seasonal groups:137
winter (November–April) and summer (May–October).138
Serum C-reactive protein (CRP) concentration was determined between 2003 and 2005 using139
a latex turbido-metric immunoassay (Olympus AU 400 analyser system for clinical chemistry,140
Wako Chemicals, Neuss, Germany), at a detection limit of 0.06 mg/L. The measured CRP141
levels were categorised as 0.04–0.99 mg/L, 1.00–1.99 mg/L and ≥2.00 mg/L (22,24).142
Subject´s chronic disease history and their overall health status was inquired in the basic143
questionnaire. For those subjects who had any abnormal findings from the examination or144
questionnaires, a specially trained physician performed a standardised physical examination145
(22-24). The physician diagnosed asthma on the basis of medical history, symptoms and146
physical status applying preset criteria (22-25).147
8148
Follow-up149
We continuously followed mortality from Statistics Finland using the subjects´ individual150
identification numbers to track participants from baseline examination through 31 December151
2011 (29).152
153
Statistical analysis154
We constructed our models to analyse associations between obstruction and low s-25(OH)D155
primarily based on previous Finnish publications. As such, we previously analysed factors156
which were associated with obstruction in the same population sample (25) and others with s-157
25(OH)D in another Finnish data set (30,31). Factors which were associated with obstruction158
and s-25(OH)D previously included age, education (in years), leisure physical activity, BMI159
and smoking history. In addition, CRP and sex were associated with obstruction and s-160
25(OH)D in this material, and a history of asthma represented a possible confounding factor161
for obstruction. All these variables appeared relevant to our study; thus, we included them all162
in our analysis here. Additionally, we analysed the modifying effect of season of s-25(OH)D163
blood sampling (5,30,31).164
We analysed the cross-sectional associations between obstruction and baseline characteristics165
using logistic regression, expressing results as model-adjusted odds ratios (ORs) with 95%166
confidence intervals (CIs). We analysed the strength of the associations of obstruction and s-167
25(OH)D with mortality in the cohort study design using Cox’s proportional hazards168
regression model. The results were expressed as model-adjusted hazard ratios (HRs) with169
95% CIs. We constructed three main models: adjusting for age and sex (1); further for170
9smoking (2); and finally also for leisure physical activity, education, BMI, asthma and serum171
C-reactive protein (3, multivariate model), which were also considered potential confounding172
factors. Whether s-25(OH)D, season of blood sample collection and obstruction modified the173
effects of each other were examined by entering their first-degree interaction terms into the174
multivariate models. Statistical significance was tested using the likelihood ratio test. Finally,175
to explore the proportional hazards assumption of the Cox’s model and to test the adequacy of176
the long follow-up, we compared the results from the full model between the follow-up times177
of 0–10 years, 11–20 years and >20 years from baseline. In addition, we also restricted the178
follow-up experience to the years 2005 to 2011 to explore influence of the fortification of179
food with vitamin D that was introduced in Finland in 2003. We analysed s-25(OH)D as both180
categorical (tertiles) and ordinary-scaled variables throughout the study. All analyses were181
performed using SAS System for Windows (version 9.3, SAS Institute, Inc., Cary, NC, USA)182
and IBM´s SPSS (version 24).183
184
Ethical considerations185
The Mini-Finland Health Survey predated current legislation on ethics in medical research.186
However, all participants were fully informed about the study, participated voluntarily and the187
use of their information for medical research was explained to them. Agreeing to participate188
in the baseline health examination was considered informed consent. Statistics Finland189
approved the linkage of national mortality data to the survey data used here (29).190
This study does not fall under the purview of laws regarding medical research, thus, the study191
protocol does not violate any ethical considerations or standards, according to a statement192
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from the Medical Ethics Committee of the Hospital District of Helsinki and Uusimaa in193
Finland (June 2013).194
195
Results196
Table 1 presents the baseline characteristics and their prevalence. At baseline, the cohort197
included 311 (4.7%) subjects with obstruction. Mean FEV1 was 2.1 l/s (standard deviation198
(SD) 1.0) in obstructive and 3.3 l/s (SD 1.0) in non-obstructive subjects, while mean199
concentrations of s-25(OH)D reached 39.1 nmol/L (SD 18.8) and 43.6 nmol/L (SD 19.5),200
respectively.201
We found an inverse association between obstruction and s-25(OH)D (Table 1). The season202
of blood sample collection did not modify that association (p=0.68 for the interaction).203
By the end of 2011, 3530 (52.9%) deaths in the study population occurred, while 247 (79.4%)204
of the subjects with obstruction died. Obstruction and low s-25(OH)D independent of one205
another predicted mortality (Table 2). HR (95% CI) for the subjects with obstruction was 1.46206
(1.28–1.68) when those without obstruction were used as the reference, while for s-25(OH)D207
from the lowest to highest tertile, HRs were 1 (reference), 0.92 (0.85–1.00) and 0.84 (0.78–208
0.92), respectively. Low s-25(OH)D did not confound the association between obstruction209
and mortality (Table 3).210
A statistically significant interaction (p=0.007) emerged between obstruction and s-25(OH)D211
tertiles when entered as a categorical variable: among subjects with obstruction HR (95% CI)212
was 0.57 (0.40–0.80) in the third tertile, whereas among those without obstruction the213
corresponding HR was 0.89 (0.81–0.98) (Table 4). The season of blood sample collection did214
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not further modify or confound the associations of obstruction and s-25(OH)D with mortality215
(data not shown).216
Finally, we used multivariate models to analyse the follow-up time strata of 0–10 years, 11–217
20 years and >20 years from baseline. The primary findings remained largely unchanged (data218
not shown). However, when the follow-up experience was restricted to the years 2005 to 2011219
(21 deaths in 85 subjects with airway obstruction), the baseline s-25(OH)D did not anymore220
predict mortality (p-value for trend 0.32); HRs from the lowest to highest tertile were 1221
(reference), 0.90 (0.76–1.07) and 0.88 (0.74–1.05), respectively.222
223
Discussion224
In our study airway obstruction and low s-25(OH)D independent of each other predicted225
mortality during the follow-up of 33 years. However, the association between low s-25(OH)D226
and mortality was stronger in those with obstruction than others.227
In accordance with previous studies, we observed an inverse cross-sectional association228
between obstruction and s-25(OH)D, which was partly explained by other factors. COPD is229
evidently associated with low s-25(OH)D (1,9-11,14). Previously, vitamin D supplementation230
improved lung functions among ever-smokers with vitamin D-deficiency or COPD and231
decreased COPD exacerbations (32,33). Yet, the association between COPD and low s-232
25(OH)D is complex, multiple factors tend to confound it and previous findings appear233
contradictory (1,12). COPD and low s-25(OH)D have both shown associations with both234
chronic diseases and many factors predicting morbidity, such as ageing, smoking and reduced235
physical activity (1,3,6,13,30,34,35). Furthermore, low s-25(OH)D and s-25(OH)D236
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metabolites might affect COPD pathophysiology and co-morbidities, such as osteoporosis,237
cardiovascular diseases and respiratory infections (1,3,12,20).238
In our study obstruction and low s-25(OH)D predicted mortality independently of each other239
and independently of other confounding factors. Comparisons of the results between previous240
studies and the present one are difficult because of the wealth of factors discussed above241
(1,3,6,12,13,30,34,35). In two studies with follow-up times from 10 to 14 years, low s-242
25(OH)D did not predict mortality among subjects with obstruction (19,20). Another study243
adjusted for common cardiovascular risk factors revealed an association between low s-244
25(OH)D and mortality among those with normal lung function (19). In a third study with an245
18-year follow-up, low s-25(OH)D predicted mortality among the subjects with obstruction;246
however, this resulted primarily from the higher age and more negative cardiovascular risk247
factor profile of those with a low s-25(OH)D (21). In that study, the cut-off limit for the248
lowest s-25(OH)D tertile was <50.9 nmol/L which was much higher than our cut-off limit of249
<33 nmol/L.250
In our study the association between low s-25(OH)D and mortality appeared pronounced251
among the subjects with obstruction.  Albeit statistically significant, this interaction may252
result from chance alone because of small numbers of subjects. Nevertheless, if replicated in253
future studies, intervention trials and therapeutic implications may prove justified.254
Our study’s strength lies in its continuous 33-year follow-up of a population sample255
representing adult Finns from a national health examination survey with a 90% participation256
rate (22,23). Specially trained expert professionals performed examinations using257
standardised methods (22-24). The causes and dates of death were obtained from death258
certificates signed by the physicians responsible for their care (22,29). An additional strength259
lies in the naturally low s-25(OH)D in our study population; when the baseline survey was260
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executed, no vitamin D fortification was used and working outside in summertime under the261
sun remained common (22,23). The use of vitamin D supplements complicates and confounds262
analyses in newer datasets (1,3,12,30) whereas it rarely appeared among Finnish adults at the263
time of our baseline survey. In addition, the concentration of s-25(OH)D remains stable in264
long-term stored blood samples (36), although the 20 years between blood sampling and265
analyses might affect the s-25(OH)D concentrations measured.266
The small sample size is the primary limitation in our study—our material carried no267
statistical power for more specific analyses. Therefore, such topics as the specific causes of268
death and degree of obstruction remain unanalysed. This same material resulted in previous269
publications regarding the influence of obstruction and s-25(OH)D, respectively, on270
cardiovascular and coronary mortality and the severity of obstruction and all-cause mortality271
(5,25,37). In addition, no bronchodilation test was performed; thus, we maybe have,272
incorrectly, categorised some reversible obstructions as chronic. Unfortunately, we had no273
data about COPD´s exacerbations and could, therefore, not consider this possible confounder.274
Additionally, no absolute definitions for COPD, obstruction or low s-25(OH)D exist, although275
clinicians use definitions and cut-off limits for both (2,4,6,27). Therefore, the results from276
studies (this and others) may not be directly comparable, a problem previously observed277
(3,10,37). There is remarkable seasonal and other variation in s-25(OH)D levels (38) but,278
unfortunately, only one blood sample was taken in our study. An additional limitation appears279
in the markedly improved s-25(OH)D among Finns between 2000 and 2011 resulting from280
the vitamin D fortification policy initiated after 2003 (2) and changes in smoking habits.281
However, the prevalence of obstruction remained unchanged in Finland between the Mini-282
Finland (1978–1980) and Health 2000 Surveys (7,39). Furthermore, other baseline283
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characteristics may have changed during follow-up exerting some influence on our results.284
This limitation typically accompanies cohort studies.285
286
Conclusions287
In conclusion, airway obstruction and low s-25(OH)D independently predict mortality; an288
outcome which a physician should consider when treating high-risk groups. If not replicated289
in future, the interaction we found for obstruction and low s-25(OH)D upon mortality does290
not justify causal inference.291
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   Table 1
     Baseline characteristics and their associations with airway obstruction (FEV1/FVC below LLN) in the study population from the logistic regression analyses
Characteristics Total (n) Obstruction (n)¹ OR² 95% Cl OR³ 95% Cl
Vitamin D status4 First tertile (5–32 nmol/L) 2177 131 1 1
Second tertile (33–48 nmol/L) 2284 101 0.79 0.59–1.08 0.93 0.70–1.23
Third tertile (49–180 nmol/L) 2215 79 0.61 0.44–0.85 0.75 0.55–1.02
p (for trend) 0.001 0.07
Age (in years) Mean 50.5, SD ± 13.75 311 1.67 1.50–1.88 1.66 1.45–1.89
p (for trend) <0.001 <0.001
Sex Male 3091 207 1 1
Female 3585 104 0.38 0.30–0.48 0.58 0.43–0.79
p (for heterogeneity) <0.001 <0.001
Smoking Never smoker 3690 92 1 1
Former smoker 1388 79 2.03 1.43–2.88 2.20 1.54–3.15
Current smoker, 1–19
cigarettes/day 991 83 3.90 2.77–5.48 3.42 2.39–4.90
Current smoker, ≥20
cigarettes/day 607 57 4.81 3.23–7.17 4.41 2.91–6.70
p (for heterogeneity) <0.001 <0.001
Asthma No 6558 280 1 1
Yes 118 31 8.82 5.65–13.78 11.43 7.11–18.36
p (for heterogeneity) <0.001 <0.001
Leisure physical activity Inactive 2349 155 1 1
Occasionally active 3279 133 0.65 0.51–0.82 0.78 0.61–1.01
Regularly active 1048 23 0.36 0.23–0.57 0.51 0.32–0.82
p (for heterogeneity) <0.001 0.009
Educational level Basic 4480 261 1 1
Intermediate 1431 33 0.48 0.33–0.70 0.51 0.35–0.75
Higher 765 17 0.49 0.30–0.82 0.56 0.33–0.94
p (for heterogeneity) <0.001 <0.001
BMI <20 310 32 1 1
20–24.99 2733 135 0.39 0.26–0.59 0.43 0.27–0.67
25–29.99 2632 105 0.26 0.17–0.40 0.28 0.18–0.45
30–34.99 826 32 0.26 0.15–0.44 0.26 0.15–0.45
≥35 175 7 0.35 0.15–0.82 0.32 0.13–0.78
p (for trend) <0.001 <0.001
CRP6 0.04–0.99 mg/L 3180 107 1 1
1–1.99 mg/L 1528 77 1.26 0.93–1.71 1.22 0.89–1.68
≥2.00 mg/L 1968 127 1.43 1.09–1.88 1.16 0.86–1.55
p (for trend) 0.01 0.35
     ¹ FEV1/FVC below LLN.
     ² Odds ratio (OR) with 95% confidence intervals (CIs), age adjusted for sex, sex adjusted for age and the other factors adjusted for age and sex.
     ³ OR with 95% CIs in a multivariate model adjusted for all factors listed in this table.
        4 Concentration of 25-hydroxyvitamin D (25(OH)D) in tertiles
        5 SD, standard deviation; range 61, 30–91 years.
         6 Concentration of C-reactive protein.
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Characteristics Deaths (n) HR¹ 95% CI HR² 95% CI
Obstruction3 No 3283 1 1
Yes 247 1.68 1.48–1.92 1.46 1.28–1.68
p (for heterogeneity) <0.001 <0.001
Vitamin D status4 First tertile (5–32 nmol/L) 1331 1 1
Second tertile (33–48 nmol/L) 1165 0.89 0.82–0.96 0.92 0.85–1.00
Third tertile (49–180 nmol/L) 1034 0.77 0.71–0.84 0.84 0.78–0.92
p (for trend) <0.001 <0.001
Age Years, ±1 SD Mean 59.0, SD ± 12.2, Range 615 4.42 4.23–4.63 4.49 4.28–4.71
p (for trend) <0.001 <0.001
Sex Male 1759 1 1
Female 1771 0.54 0.51–0.58 0.63 0.58–0.68
p (for heterogeneity) <0.001 <0.001
Smoking Never smoker 1845 1 1
Former smoker 748 1.12 1.02–1.23 1.12 1.01–1.23
Current smoker, 1–19
cigarettes/day 563 1.86 1.68–2.06 1.72 1.55–1.91
Current smoker, ≥20
cigarettes/day 374 2.73 2.41–3.09 2.35 2.06–2.67
p (for heterogeneity) <0.001 <0.001
Asthma No 3456 1 1
Yes 74 1.05 0.83–1.32 0.95 0.75–1.20
p (for heterogeneity) 0.70 0.68
Leisure physical
activity Inactive 1498 1 1
Occasionally active 1623 0.78 0.72–0.83 0.87 0.81–0.94
Regularly active 409 0.69 0.62–0.77 0.87 0.78–0.98
p (for heterogeneity) <0.001 <0.001
Educational level Basic 2750 1 1
Intermediate 559 0.87 0.79–0.95 0.92 0.84–1.01
Higher 221 0.68 0.59–0.78 0.73 0.64–0.84
p (for heterogeneity) <0.001 <0.001
BMI <20 138 1 1
20–24.9 1174 0.59 0.50–0.71 0.63 0.53–0.75
25–29.9 1514 0.61 0.51–0.72 0.65 0.54–0.78
30–34.9 576 0.74 0.62–0.90 0.74 0.61–0.89
≥35 128 0.86 0.68–1.10 0.78 0.61–1.00
p (for trend) 0.005 0.196
CRP6 0–0.99 mg/L 1234 1 1
1–1.99 mg/L 913 1.22 1.12–1.33 1.15 1.05–1.26
≥2 mg/L 1383 1.67 1.54–1.80 1.46 1.35–1.59
p (for trend) <0.001 <0.001
  ¹ Hazard ratio (HR) with 95% confidence intervals (CIs), age adjusted for sex, sex adjusted for age and other factors adjusted for age and sex.
  ² HR with 95% CIs in a multivariate model adjusted for all factors listed in this table.
  ³ FEV1/FVC over or below LLN.
  4 Concentration of 25-hydroxyvitamin D (25(OH)D) in tertiles.
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  5 SD, standard deviation; range 30–91 years.
  6 Concentration of C-reactive protein.
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Table 3
Association between airway obstruction (FEV1/FVC below LLN) and mortality¹ in variously adjusted models from 1978–1980 through 31 December
2011
Model adjusted for HR² 95% CI
Age and sex No obstruction³ 1
Obstruction³ 1.69 1.49–1.93
Age, sex, vitamin D status4 No obstruction³ 1
Obstruction³ 1.68 1.48–1.92
Age, sex, smoking history No obstruction³ 1
Obstruction³ 1.53 1.34–1.74
Age, sex, smoking history, vitamin D status4 No obstruction³ 1
Obstruction³ 1.52 1.33–1.73
Full model5, without vitamin D status4 No obstruction³ 1
Obstruction³ 1.46 1.27–1.67
Full model5with vitamin D status4 No obstruction³ 1
Obstruction³ 1.46 1.28–1.67
¹ There were 3283 deaths in subjects without obstruction and 247 in those with obstruction.
² Hazard ratio (HR) with 95% confidence intervals (CIs).
³ FEV1/FVC over or below LLN.
4 Concentration of 25-hydroxyvitamin D (25(OH)D) in tertiles.
5 Multivariate model adjusted for age, sex, smoking, obstruction, asthma, education (in years), leisure physical activity, BMI and CRP.
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   Table 4434
    Association between airway obstruction (FEV1/FVC below LLN), vitamin D status and mortality from 1978–1980 through 31 December 2011435
Characteristics No obstruction Obstruction
Vitamin D status¹ Total (n) Deaths (n) HR² 95% CI Total (n) Deaths (n) HR² 95% CI
First tertile (5–32 nmol/L) 2046 1220 1 131 111 1
Second tertile (33–48 nmol/L) 2183 1083 0.96 0.87–1.05 101 82 0.96 0.71–1.31
Third tertile (49–180 nmol/L) 2136 980 0.89 0.81–0.98 79 54 0.57 0.40–0.80
p-value for trend 0.002 0.002
p-values for interactions ‘obstruction*vitamin D status’
Vitamin D status as an ordinary scaled variable:                                                 0.02
Vitamin D status as a categorical variable:                                                          0.007
¹ Concentration of 25-hydroxyvitamin D (25(OH)D).
² HR with 95% CIs in multivariate model adjusted for age, sex, smoking, obstruction, asthma, education (in years), leisure physical activity, BMI and CRP.
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